Benzinga | Oct 20, 2021 06:15AM EDT

BMO Capital Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $19

BMO Capital analyst Matthew Luchini initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rating and announces Price Target of $19.